天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >(2R,3R)-Glucodistylin
(2R,3R)-Glucodistylin
  • (2R,3R)-Glucodistylin

(2R,3R)-Glucodistylin NEW

Price $3690
Package 5mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: (2R,3R)-Glucodistylin CAS No.: 27297-45-6
Supply Ability: 10g Release date: 2024/11/19

Product Introduction

Bioactivity

Name(2R,3R)-Glucodistylin
Description(2R,3R)-Glucodistylin is a natural product for research related to life sciences. The catalog number is TN6272 and the CAS number is 27297-45-6.
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Keywords(2R,3R) Glucodistylin | Taxifolin 3-O-glucoside | Glucodistylin | (2R,3R)Glucodistylin

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/10mg
VIP1Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-06-28
$29.00/100mg
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY